Spectrum Pharmaceutecals Inc (SPPI)

[dcaf7]

Experts opinion on Poziotinib. Just published, "Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?"
From the paper: "In accordance with the National Comprehensive Cancer Network, the current optimal treatment for patients with metastatic HER2 exon 20 insertion mutation, in second line, T-DXd, seems to be most appropriate. Nevertheless, HER2-specific TKIs with better selectivity and reduced toxicity are expected to yield at least similar outcomes in the near future. In the interim, poziotinib presents a treatment option that should not be disregarded entirely. It is crucial to explore the patient population and dosages for which this strategy can offer a beneficial effect while maintaining an acceptable quality of life."
https://www.jto.org/article/S1556-0864(23)00548-8/fulltext
Should ASRT work on Pozi?